title: The role of chemotherapy in biliary tract carcinoma.
abstract: Cholangiocarcinoma is a rare malignancy associated with poor prognosis and high mortality. Surgical resection is the only chance for cure depending on careful patient selection. There are no well-conducted studies regarding the role of adjuvant chemotherapy. Preliminary data suggest that liver transplantation could offer long-term survival in selected patients when combined with neoadjuvant chemoradiotherapy. The literature regarding treatment results with specific regimens in the adjuvant setting is limited and no general recommendation can be given. In patients with locally advanced or metastatic disease, most studies are small, non-randomized phase II trials, and many studies comprise a mix of bile duct cancers, gallbladder cancer, and either pancreatic or hepatocellular cancers. In metastatic cancer, phase II studies with several cytotoxics, including gemcitabine, the platinums, and the fluoropyrimidines, have shown a modest and often short-lasting activity. No single chemotherapy agent or combination regimen can therefore be recommended as a standard of care at present. In this review, we give an overview of chemotherapy in the adjuvant, neoadjuvant, and advanced settings.
authors.affiliation: Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium.
authors.forename: C
authors.initials: C
authors.lastname: Verslype
authors.forename: H
authors.initials: H
authors.lastname: Prenen
authors.forename: E
authors.initials: E
authors.lastname: Van Cutsem
references.citation: J Clin Oncol. 2006 Jul 1;24(19):3069-74
references.pmid: 16809731
references.citation: Ann Oncol. 2002 Aug;13(8):1192-6
references.pmid: 12181241
references.citation: Jpn J Clin Oncol. 2005 Feb;35(2):68-73
references.pmid: 15709089
references.citation: Am J Clin Oncol. 2000 Aug;23(4):425-8
references.pmid: 10955877
references.citation: Ann Oncol. 2004 Sep;15(9):1339-43
references.pmid: 15319238
references.citation: Eur J Cancer. 1993;29A(5):698-703
references.pmid: 8471327
references.citation: Oncology. 2007;72(1-2):105-10
references.pmid: 18025804
references.citation: Ann Oncol. 1996 Aug;7(6):593-600
references.pmid: 8879373
references.citation: Ann Oncol. 2008 Jan;19(1):99-103
references.pmid: 17846018
references.citation: Eur J Cancer. 2005 Feb;41(3):398-403
references.pmid: 15691639
references.citation: Br J Cancer. 2005 May 9;92(9):1650-4
references.pmid: 15856037
references.citation: Ann Oncol. 2004 Mar;15(3):478-83
references.pmid: 14998852
references.citation: Ann Surg. 2001 Oct;234(4):507-17; discussion 517-9
references.pmid: 11573044
references.citation: Ann Surg. 2005 Sep;242(3):451-8; discussion 458-61
references.pmid: 16135931
references.citation: Ann Surg. 2007 Nov;246(5):734-40
references.pmid: 17968163
references.citation: Br J Cancer. 2008 Jan 29;98(2):309-15
references.pmid: 18182984
references.citation: Cancer. 2006 Mar 15;106(6):1339-46
references.pmid: 16475213
references.citation: Cancer. 2007 Sep 15;110(6):1307-12
references.pmid: 17628484
references.citation: Gastroenterology. 2002 Apr;122(4):985-93
references.pmid: 11910351
references.citation: Ann Oncol. 2001 Oct;12(10):1403-6
references.pmid: 11762811
references.citation: Br J Cancer. 2007 Mar 26;96(6):896-902
references.pmid: 17325704
references.citation: Hepatogastroenterology. 2001 May-Jun;48(39):783-9
references.pmid: 11462924
references.citation: N Engl J Med. 1999 Oct 28;341(18):1368-78
references.pmid: 10536130
references.citation: Anticancer Drugs. 1998 Jun;9(5):393-7
references.pmid: 9660535
references.citation: Br J Cancer. 2004 Nov 15;91(10):1769-74
references.pmid: 15505626